Guidelines and Recommendations

 

The below links to evidence-based clinical guidelines and recommendations provide guidance on the use of emicizumab in patients with hemophilia A.

National Hemophilia Foundation Medical and Scientific Advisory Council (MASAC Document #258)

Recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors.

World Federation of Hemophilia Guidelines for the Management of Hemophilia, 3rd edition

Srivastava A, Santagostino E, Dougall  A, et al.  Haemophilia. 2020; DOI: 10.1111/hae.14046.